Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review.

Tianyuan Xu,Hanxu Guo, Jun Xie,Yanyan He,Jianping Che,Bo Peng,Bin Yang,Xudong Yao

Frontiers in oncology（2023）

引用 0|浏览6

暂无评分

摘要

Immunochemotherapy may be a promising first-line option for advanced or metastatic UTUC selected with specific genomic or phenotypic signatures, and blood-based analyses incorporating ctDNA profiling provide precise longitudinal monitoring.

查看译文

关键词

upper tract urothelial carcinoma, immunochemotherapy, TP53, MDM2, ErbB2, luminal-infiltrated, circulating tumor DNA (ctDNA), case report, sintilimab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要